CSIMarket
 
Schrodinger Inc   (NASDAQ: SDGR)
Other Ticker:  
 
 
Price: $23.9900 $-1.61 -6.271%
Day's High: $25.58 Week Perf: 24.82 %
Day's Low: $ 23.91 30 Day Perf: 4.76 %
Volume (M): 227 52 Wk High: $ 28.47
Volume (M$): $ 5,454 52 Wk Avg: $21.03
Open: $25.58 52 Wk Low: $16.60



 Market Capitalization (Millions $) 1,747
 Shares Outstanding (Millions) 73
 Employees 378
 Revenues (TTM) (Millions $) 208
 Net Income (TTM) (Millions $) -187
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 7

Schrodinger Inc
Schrodinger Inc is a leading computational chemistry and biophysics software company that was founded in 1990 by William Goddard III, Michael Levitt, and Peter Kollman. Schrodinger Inc is named after physicist Erwin Schrodinger, who was awarded the Nobel Prize in Physics in 1933 for his contribution to the development of quantum mechanics.

Schrodinger Inc is headquartered in New York City and has additional offices in Europe and Asia. The company is known for its state-of-the-art computational chemistry and biophysics software tools that enable scientists to accurately simulate and predict the behavior of molecules and other biological systems. These tools are used extensively in drug discovery, materials science, and development of biotechnology products.

The company's software platform, Schrodinger Suite, includes a range of software packages that help scientists perform a variety of tasks such as molecular dynamics simulations, ligand-based and structure-based drug design, and protein structure prediction. The software platform is also used to predict and understand the interactions of molecules with biological targets, allowing for more efficient drug discovery.

Schrodinger Inc has a diverse customer base, including academic and government research institutions, biotechnology and pharmaceutical companies, and chemical and materials manufacturers. The company's software tools have been used in several drug discovery projects that have led to the development of successful drugs, including the HIV protease inhibitor Saquinavir and the antipsychotic drug Aripiprazole.

Schrodinger Inc is also actively involved in scientific research and development. The company has a team of scientists who work on developing new software tools and applications, as well as collaborating with academic and industrial partners on various research projects.

Overall, Schrodinger Inc is a leading software company that has made significant contributions to the fields of computational chemistry and biophysics. The company's innovative software tools have played an important role in advancing drug discovery, materials science, and biotechnology, and will continue to be a major force in the scientific community for years to come.


   Company Address: 1540 Broadway New York 10036 NY
   Company Phone Number: 295-5800   Stock Exchange / Ticker: NASDAQ SDGR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CUE        14.29% 
IOBT        0.9% 
CDNS   -0.13%    
CERT        42.65% 
CGEN        7.81% 
RVTY   -3.2%    
• View Complete Report
   



Business Update

Schrodinger Set to Showcase Innovations at Key Investor Conferences in March 2025,

Published Mon, Feb 24 2025 8:43 PM UTC

Abstract: Schrodinger, a prominent leader in the field of computational drug discovery, has announced its participation in multiple investor conferences scheduled for March 2025. This engagement presents an opportunity for the company to discuss its groundbreaking developments in pharmaceutical sciences and computational chemistry with investors and industry stakeholders.Adv...

Business Update

Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Published Tue, Nov 19 2024 3:56 PM UTC

Schrodinger Expands Its Talent Pool with Strategic RSU Grants Under Nasdaq Listing RuleIn a notable move to bolster its workforce and align with industry standards for employee compensation, Schrodinger, Inc. (Nasdaq: SDGR) has disclosed the granting of restricted stock units (RSUs) to four newly hired employees. This announcement, made on November 14, 2024, expands upon Sc...

Business Update

Schrödinger Set to Showcase Promising Preclinical Data on SGR-3515 and PRMT5-MTA at EORTC-NCI-AACR Symposium Amid Im...

Published Wed, Oct 9 2024 12:47 PM UTC

Schrödinger Set to Showcase Promising Preclinical Data on SGR-3515 and PRMT5-MTA at EORTC-NCI-AACR Symposium Amid Impressive Revenue Growth In an exciting development within the biopharmaceutical sector, Schrödinger Inc. (Nasdaq: SDGR) has announced it will present new preclinical data regarding its investigational compounds SGR-3515 and the PRMT5-MTA inhibitor program at th...

Schrodinger Inc

Schrodinger Inc Reports Major Decline in Financial Performance, with Deficit of $-0.76 per Share in Q1 2024

Schrodinger Inc, a leading provider of chemical simulation software for pharmaceutical and biotechnology industries, recently reported a significant decline in its financial performance for the first quarter of 2024. The company posted a deficit per share of $-0.76, compared to a deficit of $0.38 in the prior reporting season and a profit of $1.75 a year ago. This drop in profitability was accompanied by a sharp decrease in revenue, which fell by -44.599% year-over-year to $35.89 million.
The net deficit for the period amounted to $54.724 million, a stark contrast to the net income of $129.136 million reported in the same period last year. The decline in revenue and profitability can be attributed to a slowdown in demand, as evidenced by the decrease in accounts receivable to $19.8 million.

Schrodinger Inc

Major Pharmaceutical Preparations company reports deficit of $-0.38 per share in Q4 2023

Schrodinger Inc's recent financial performance paints a concerning picture for investors. Despite a substantial increase in revenue, the company still posted a loss in the fourth quarter of 2023. This raises red flags about the company's ability to effectively manage its expenses and generate profits.
The fact that Schrodinger Inc's net deficit for the fourth quarter of 2023 was larger than the previous year is particularly troubling. This suggests that the company's financial situation may be worsening, rather than improving. Additionally, the significant increase in accounts receivable could indicate that the company is struggling to collect payments from its customers, which could impact its cash flow and overall financial health.







Schrodinger Inc's Segments
On-premise software    35.27 % of total Revenue
Hosted software    25.38 % of total Revenue
Software maintenance    16.29 % of total Revenue
Professional services    5.87 % of total Revenue
Revenue from contracts with customers    82.82 % of total Revenue
Software contribution    9 % of total Revenue
Software products and services    91.81 % of total Revenue
Drug discovery services revenue from contracts with customers    8.1 % of total Revenue
Drug discovery contribution    1.71 % of total Revenue
On Premise Software    35.27 % of total Revenue
Software    91.81 % of total Revenue
Drug discovery    9.81 % of total Revenue
United States    70.9 % of total Revenue
APAC    15.2 % of total Revenue
EMEA    14.82 % of total Revenue
Rest of World    0.7 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com